论文部分内容阅读
为了得到性能改善的组织型纤溶酶原激活剂（ｔ－ＰＡ）突变体，运用Ｐｒｏｍｅｇａ公司研制的改良的寡核苷酸诱导的定位突变技术，成功地构建了 ｔ－ＰＡ ｃＤＮＡ定位点突变、缺失突变及置换突变等多种突变体。ＤＮＡ序列分析表明突变频率达７５％以上。
In order to obtain the tissue plasminogen activator (t-PA) mutant with improved performance, we successfully constructed the t-PA cDNA site mutation by using the modified oligonucleotide-induced localization mutation technology developed by Promega company. Mutations and replacement mutations such as a variety of mutants. DNA sequence analysis showed that the mutation frequency was above 75%.